secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0000950170-25-082717
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta appoints Shawn Rose as CMO & Head of R&D; David Shook resigns effective June 6
--------------------------------------------------------------------------------

- Shawn Rose, M.D. Ph.D, joins as CMO and Head of R&D starting June 23, 2025, succeeding David Shook.
- Dr. Shook resigned to pursue other oncology opportunities; will consult through July 11.
- Dr. Rose brings experience from Vividion, Magenta, Janssen, and BMS, with work on Sotyktu, Stelara, Tremfya.
- Company reaffirms focus on allogeneic NK cell therapies for autoimmune disease.
- Annual meeting results: all three Class II director nominees elected; Ernst & Young ratified as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/0000950170-25-082717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025082717/nktx-20250603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-082717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer